Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.520
-0.070 (-1.53%)
At close: Sep 15, 2026, 4:00 PM EDT
4.520
0.00 (0.00%)
After-hours: Sep 15, 2026, 4:04 PM EDT
Prelude Therapeutics Employees
Prelude Therapeutics had 79 employees as of December 31, 2025. The number of employees decreased by 52 or -39.69% compared to the previous year.
Employees
79
Change (1Y)
-52
Growth (1Y)
-39.69%
Revenue / Employee
$283,848
Profits / Employee
-$765,671
Market Cap
465.54M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 79 | -52 | -39.69% |
| Dec 31, 2024 | 131 | 3 | 2.34% |
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Sep 30, 2022 | 120 | 7 | 6.19% |
| Jun 30, 2022 | 112 | 12 | 12.00% |
| Mar 31, 2022 | 118 | 13 | 12.38% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Sep 30, 2021 | 113 | 58 | 105.45% |
| Jun 30, 2021 | 100 | 49 | 96.08% |
| Mar 31, 2021 | 105 | 54 | 105.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Capricor Therapeutics | 231 |
| ARS Pharmaceuticals | 200 |
| Puma Biotechnology | 179 |
| Cabaletta Bio | 158 |
| Kyverna Therapeutics | 149 |
| Prothena Corporation | 67 |
| Entera Bio | 22 |
PRLD News
- 4 days ago - Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 5 days ago - Prelude Therapeutics receives FDA clearance for PRT13722 IND application - TheFly
- 5 days ago - Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader - GlobeNewsWire
- 5 weeks ago - Prelude Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Prelude Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TheFly
- 5 weeks ago - Prelude Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline - TheFly